Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors
WALTHAM, MA (PRWEB) October 22, 2014 -- Akeso Biomedical, Inc., a privately held company developing new solutions for the treatment of bacterial infections, microbial biofilms, and chronic wounds, announced that Dr. Anthony J. Sinskey has joined its board of directors.
Dr. Sinskey is a Professor of Microbiology and Engineering Systems at The Massachusetts Institute of Technology, or MIT. He has been a member of the MIT faculty since 1968. Dr. Sinskey also holds positions as Co-Director of the Malaysia-MIT Biotechnology Partnership Program and as Faculty Director of the Center for Biomedical Innovation. Dr. Sinskey is a co-founder and a member of the boards of directors of Metabolix, Inc. and Tepha, Inc., a co-founder and a member of the board of directors of Merrimack Pharmaceuticals, Inc., and a consultant to several chemical and biotechnology companies.
“We are delighted that Dr. Sinskey has joined the Akeso board of directors. His expertise in biotechnology and commercializing early stage technologies will be exceptionally valuable to Akeso as the Company widens its technical portfolio to include new technologies for the treatment of bacterial infections and microbial biofilms in addition to chronic wounds,” said Simon Williams, CEO of Akeso. “Tony’s knowledge will be particularly helpful as Akeso evaluates a new class of compounds, known as Fe3C, that have broad-spectrum activity against a wide range of disease-causing bacteria.”
Dr. Sinskey commented, “I am very excited to join the Akeso board of directors and help the Company position its Fe3C and silk proprietary platforms for commercial success. These technologies offer significant promise for the prevention of Campylobacter foodborne illness, the treatment of other bacterial infections and microbial biofilms, and the treatment of chronic wounds.”
About Akeso Biomedical, Inc.
Akeso Biomedical, Inc. is an early stage company focused on developing new solutions for the treatment of bacterial infections, microbial biofilms, and chronic wounds. The Company is developing products to treat these conditions using a new class of compounds, known as Fe3C, that have broad-spectrum activity against a wide range of bacteria, and a silk biomaterial technology exclusively licensed from Tufts University. Akeso’s lead Fe3C product is a feed additive designed to prevent food poisoning by Campylobacter, a bacteria that causes more cases of foodborne illness in the EU than Salmonella, E. coli and Listeria combined, with an estimated 280,000 cases in the UK and 1.3 million cases in the US each year. For more information please send inquiries to contact(at)akesobiomedical(dot)com. Akeso Biomedical, Inc. is a VIC Technology Venture Development™ portfolio company.
Bernie Prusaczyk, Chairman of the Board, AkesoBiomedical, Inc., http://www.akesobiomedical.com, 781-890-0088, [email protected]
Share this article